---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-104900"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:49:57.961594+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma Q3 2025 licensing revenue up 230% YoY to $1.28M; total assets rise 181%

## Summary
- Licensing revenue of $1.28M in Q3 2025 vs $0.39M in Q3 2024 (+230% YoY).
- Total assets $21.18M (Sep 30, 2025) vs $7.54M (Dec 31, 2024); up 181%.
- Property and equipment surged to $12.06M from $0.51M (+2,100%) on land buys in Taiwan.
- Two land acquisitions completed in Q3: Puli ($7.67M) and Longtan ($3.3M) for R&D and API cultivation.
- Company maintains asset-light licensing model with multiple CNS, ophthalmology, oncology licensing agreements.

## SEC filing metadata
- accession: 0001213900-25-104900
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390025104900/0001213900-25-104900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390025104900/ea0263481-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-104900
- JSON: https://secwatch.observer/filing/0001213900-25-104900.json
- Plain text: https://secwatch.observer/filing/0001213900-25-104900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.